Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 5, 2008, Pages 785-790

  Kroschinsky, Frank P ^a   Friedrichsen, Kai ^b   Mueller, Juliane ^a   Pursche, Stefan ^a   Haenel, Mathias ^b   Prondzinsky, Roland ^c   Ehninger, Gerhard ^a   Schleyer, Eberhard ^a,c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c Carl von Basedow Hospital   (Germany)

Author keywords

CHOEP; Etoposide; Lymphoma; Oral administration; Pharmacokinetics

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOFOS; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; LYMPHOMA; MALE; PRIORITY JOURNAL; URINALYSIS;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISOLONE; SOFTWARE; VINCRISTINE;

EID: 39749147683     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0535-3     Document Type: Article

References (24)

1. Adde M, Enblad G, Hagberg H, Sundstrom C, Laurell A (2006) Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14). Med Oncol 23:283-293
2. Celsing F, Widell S, Merk K, Bernell P, Grimfors G, Hedlund A, Liliemark J, Svedmyr E, Ösby E, Björkholm M (1998) Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphoma. Ann Oncol 9(11):1213-1217
3. Cunningham D, McTaggart L, Soukop M, Cummings J, Forrest GJ, Stuart JF (1986) Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Med Oncol Tumor Pharmacother 3:95-99
4. DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 17:3362-3365
5. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
6. Fujiwara Y, Ohune T, Okusaki K, Niitani K, Sumiyoshi H, Takemoto Y, Yamaoka N, Yamakido M (1996) Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. Cancer Chemother Pharmacol 37:327-331
7. Hande K, Messenger M, Wagner J, Krozely M, Kaul S (1999) Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 5:2742-2747
8. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374-377
9. Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PF (1986) Effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 16:178-181
10. Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G (1977) Modellentwicklung in der Pharmakokinetik. Drug Res 27:904
11. Ioannides C (1996) Cytochromes P450: metabolic and toxicological aspects. CRC Press, New York, p 31
12. Joel SP, Clark PI, Heap L, Webster L, Robbins S, Craft H, Slevin ML (1995) Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol 37:125-133
13. Koppler H, Pfluger KH, Eschenbach I, Pfab R, Lennert K, Wellens W, Schmidt M, Gassel WD, Kolb T, Hassler R (1989) CHOP-VP16 chemotherapy and involved field irradiation for high-grade non-Hodkin's ymphomas: a phase II multicentre study. Br J Cancer 60(1):79-82
14. Köppler H, Pflüger KH, Eschenbach I, Pfab R, Birkmann J, Zeller W, Holle R, Steinhauer UE, Gropp C, Oehl S (1994) Randomized comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial. Ann Oncol 5:49-55
15. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE (1976) Hydroxyldaunomycin (Adriamycin) combination in malignant lymphoma. Cancer 38:1484-1493
16. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M, for the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHHNL) (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633
17. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, for the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHHNL) (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641
18. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
19. Slevin ML (1991) The clinical pharmacology of etoposide. Cancer 67:319-329
20. Slevin ML, Joel SP, Whomsley R, Devenport K, Harvey VJ, Osborne RJ, Wrigley PF (1989) The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24:329-331
21. Smyth RD, Pfeffer M, Scalzo A, Comis RL (1985) Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12:48-51
22. Toffoli G, Corona G, Basso B, Boiocchi M (2004) Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 43:441-466
23. Trümper L, Renner Ch, Klöss M, Nahler ME, Diehl V (1994) Intensification of the CHOEP regimen for high grade non-Hodgkin's lymphoma by g-CSF: feasibility of a 14-day regimen. Onkologie 17:69-71
24. Wurthwein G, Krumpelmann S, Tillman B, Real E, Schulze-Westhoff P, Jurgens H, Boos J (1999) Population pharmacokinetic approach to compare oral and i.v. administration of etoposide. Anticancer Drugs 10:807-814